Best Practice in Advanced Oesophageal
Purpose/Objective(s): RT is known to relieve dysphagia of advanced oesophageal cancer, there is no data from randomised phase III trials determining response, toxicity, or role of palliative CRT. Aims 1) to establish effective and least toxic treatment for symptom relief of advanced OC 2) determine effects of common cancer treatments on QoL and end of life care 3) establish an evidence base for patient decision making regarding the optimal management for incurable OC. Materials/Methods: 220 patients were randomised to receive a course of palliative RT [35 Gy in 15 fractions in Australia and New Zealand, (n=115) or 30 Gy in 10 fractions (n=105) in Canada and UK], or concomitant CRT with Cisplatin and 5FU (D1-4) (n=111). Dysphagia was measured using the Mellow score, toxicity using CTCAE v2, and QoL using EORTC QLQ30 and oesophagus module (OES-18). The primary end point was the proportion of patients with improved dysphagia as measured at week 9 and maintained until week 13. Results: The patients receiving radiotherapy alone showed a dysphagia response (at any point) of 67.89% compared to chemotherapy response in 73.87% (p=0.343). There was increased gastro-intestinal toxicity in patients receiving CRT (nausea (p=0.0019) and vomiting (p=0.0072)). The median survival was 210 days for CRT and 203 days for RT alone. The baseline parameters of both groups were well matched at randomisation and although the results of the trial showed equally poor survival prognosis in both arms, there were some patients (n=21) still alive at 2 years post treatment. Conclusions: CRT was associated with increased gastro-intestinal toxicity without any significant improvement in dysphagia response or median survival. Further analysis of QoL, toxicity and durable palliative response will be published. This multicentre trial reflects practice in several countries. RT alone remains an excellent tool for palliation of patients with advanced OC and should remain the standard of care. Purpose/Objective(s): Stereotactic ablative radiation (SABR) with its shorter treatment times & conformality is a promising treatment modality for patients with locoregionally confined pancreatic ductal adenocarcinoma (PDA). We conducted a prospective, single-arm phase II clinical trial to evaluate the safety, feasibility and efficacy of induction chemotherapy (ICT) followed by SABR, in subjects with borderline resectable (BR) and locally-advanced (LA) PDA. 2 year local progression-free survival (LPFS) is the primary end point and follow up is ongoing. Materials/Methods: Patients (pts) had to have biopsy-proven PDA (LA or BR). ICT consisted of four 21-day cycles of gemcitabine (d1&8 1000 mg/m2) and capecitabine (days 1-14, 650 mg/m2¬¬BID). Pts were restaged within 4 weeks post-ICT by CT imaging and, and continued to SABR if no mets or progressive disease were identified. SABR dose was 36 Gy in 3 fractions to the planning target volume (PTV) including a 2mm expansion around the gross tumor. Patients were re-staged 4 weeks following SABR to determine resectability. Results: All 34 enrolled pts (18 BR/16 LA) are included in this analysis. The average age was 71, 56% female. All 4 cycles of ICT were completed in 91% (n=31) of pts. 3 pts did not receive chemotherapy (1 died during ICT because of an arterial occlusion, 1 died after consent, 1 had a MI during chemotherapy). There were 3% (n=1) grade 3 GI, 10% (n=3) grade 3 hematological, and 3% (n=1) grade 4 hematological toxicities with ICT. All 31 pts who completed chemotherapy also completed SABR. Mean PTV was 24.3 cm3 with no acute SABR toxicities. Of those 31, 40% (n=12-10BR, 2LA) proceeded to pancreaticoduodenectomy-10/10 BR and 1/2 LA patients had R0 resections; pCR in 1 BR. 8 patients with BR disease did not receive surgery (3 with progressive local disease, 1 had a myocardial infarction, 1 declined surgery, 2 developed metastatic disease, 1 unresectable at surgery). There were 5.8% (n=2) grade 3 (pseudoaneurysm and hepatic abscess), 5.8% (n=2) grade 4 (ICU admission for CVA and portal vein thrombosis) post-operative toxicities (Clavien scoring). For BR pts 1-year LPFS was 86%, and median freedom from any recurrence was 25.5 months. For LA pts 1-year LPFS was 100%, and median freedom from any recurrence was 22.5 months. Out of 20 evaluable patients with both pre-ICT and post SABR CA 19-9 values, the mean value decreased from 867 to 177 (p=0.009) with decreases >50% in 7/9 BR and 7/11LA cases. Conclusions: This is the first prospective phase II study to investigate the feasibility and efficacy of induction chemotherapy, SABR, followed by surgical resection. This approach appears promising in facilitating an R0 resection in BR patients with acceptable toxicity. With continued follow-up, the efficacy of this approach can be defined. 
